Vialto Partners, a tax and immigration services provider, is restructuring its debt following its spinoff from PwC and acquisition by Clayton Dubilier & Rice. The plan includes a $225 million equity injection and a reduction of approximately $700 million in existing debt, with HPS Investment Partners becoming a minority equity owner while CD&R maintains its majority stake.
Clayton Dubilier & Rice's pursuit of a €16 billion deal to acquire half of Sanofi's consumer arm, Opella, highlights the resurgence of the leveraged-finance market. Despite past setbacks with the Morrisons buyout, banks are eager to provide funding, driven by a need to generate fees as interest rates begin to stabilize.
Sanofi's sale of a controlling stake in its Opella unit to US buyout firm Clayton Dubilier & Rice for €16 billion has concluded a year-long takeover battle marked by intense rivalry. The French drugmaker faced fierce opposition from Paris-based PAI Partners, which attempted to disrupt the deal, leading to public disputes and political tensions.
Sanofi is moving forward with a deal to sell a controlling 50% stake in its consumer health business, Opella, to Clayton Dubilier & Rice for approximately €16 billion ($17.3 billion). Bpifrance will hold a 2% minority stake, ensuring job security in France amid concerns over potential job losses. The transaction is expected to close by Q2 2025, allowing Sanofi to focus on its biopharmaceuticals.
Sanofi has agreed to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice for approximately 15 billion euros. The deal includes guarantees for job and production retention in France, with the French public investment bank Bpifrance acquiring a 1% stake. This move follows concerns from labor unions about potential job losses amid the sale.
Sanofi is in negotiations with private equity firm Clayton Dubilier & Rice to sell a 50% controlling stake in its consumer health business, Opella, potentially valued at around €15 billion ($16.4 billion). This sale would allow Sanofi to focus more on its biopharmaceutical operations, which generated over €18 billion in sales in the first half of the year. Opella, known for products like Allegra and Icy Hot, operates in 100 countries and employs over 11,000 people.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
